Literature DB >> 34826654

Alexander disease: models, mechanisms, and medicine.

Tracy L Hagemann1.   

Abstract

Alexander disease is a primary disorder of astrocytes caused by gain-of-function mutations in the gene for glial fibrillary acidic protein (GFAP), which lead to protein aggregation and a reactive astrocyte response, with devastating effects on the central nervous system. Over the past two decades since the discovery of GFAP as the culprit, several cellular and animal models have been generated, and much has been learned about underlying mechanisms contributing to the disease. Despite these efforts, many aspects of Alexander disease have remained enigmatic, particularly the initiating events in GFAP accumulation and astrocyte pathology, the relation between astrocyte dysfunction and myelin deficits, and the variability in age of onset and disease severity. More recent work in both old and new models has begun to address these complex questions and identify new therapeutics that finally offer the promise of effective treatment.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34826654      PMCID: PMC8901527          DOI: 10.1016/j.conb.2021.10.002

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  57 in total

1.  Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice.

Authors:  A Messing; M W Head; K Galles; E J Galbreath; J E Goldman; M Brenner
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  Alexander disease: diagnosis with MR imaging.

Authors:  M S van der Knaap; S Naidu; S N Breiter; S Blaser; H Stroink; S Springer; J C Begeer; R van Coster; P G Barth; N H Thomas; J Valk; J M Powers
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

3.  Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.

Authors:  Tracy L Hagemann; Berit Powers; Curt Mazur; Aneeza Kim; Steven Wheeler; Gene Hung; Eric Swayze; Albee Messing
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

4.  Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain.

Authors:  Peter E Mouser; Elizabeth Head; Kwang-Ho Ha; Troy T Rohn
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

5.  Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.

Authors:  Guomei Tang; Ming D Perng; Sherwin Wilk; Roy Quinlan; James E Goldman
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

6.  Murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance.

Authors:  Kenji F Tanaka; Hirohide Takebayashi; Yoshihiko Yamazaki; Katsuhiko Ono; Masae Naruse; Takuji Iwasato; Shigeyoshi Itohara; Hiroshi Kato; Kazuhiro Ikenaka
Journal:  Glia       Date:  2007-04-15       Impact factor: 7.452

7.  Alexander disease.

Authors:  Albee Messing; Michael Brenner; Mel B Feany; Maiken Nedergaard; James E Goldman
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

8.  Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.

Authors:  Tracy L Hagemann; Berit Powers; Ni-Hsuan Lin; Ahmed F Mohamed; Katerina L Dague; Seth C Hannah; Gemma Bachmann; Curt Mazur; Frank Rigo; Abby L Olsen; Mel B Feany; Ming-Der Perng; Robert F Berman; Albee Messing
Journal:  Sci Transl Med       Date:  2021-11-17       Impact factor: 17.956

9.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease.

Authors:  Liqun Wang; Jing Xia; Jonathan Li; Tracy L Hagemann; Jeffrey R Jones; Ernest Fraenkel; David A Weitz; Su-Chun Zhang; Albee Messing; Mel B Feany
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

View more
  4 in total

Review 1.  [Research advances in the clinical genetics of leukodystrophy in children].

Authors:  Zhe-Lan Huang; Wen-Hao Zhou
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

Review 2.  Human iPSC-Derived Astrocytes: A Powerful Tool to Study Primary Astrocyte Dysfunction in the Pathogenesis of Rare Leukodystrophies.

Authors:  Angela Lanciotti; Maria Stefania Brignone; Pompeo Macioce; Sergio Visentin; Elena Ambrosini
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

3.  Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.

Authors:  Anja Holm; Stine N Hansen; Henrik Klitgaard; Sakari Kauppinen
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.766

Review 4.  Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.

Authors:  Jacob Helm; Ludger Schöls; Stefan Hauser
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.